Perrigo Reports Record Sales, Earnings and Cash Flow From Operations for F...(623) (1799) ...),Health

Date:8/18/2009

623) (1,799) --- ------ ------ Net increase (decrease) in cash and cash equivalents (2,467) 288,299 11,287 Cash and cash equivalents of continuing operations, beginning of period 318,599 30,301 19,018 Cash balance of discontinued operations, beginning of period 5 4 - --- --- --- Cash and cash equivalents, end of period 316,137 318,604 30,305 Less cash balance of discontinued operations, end of period (4) (5) (4) -- -- -- Cash and cash equivalents of continuing operations, end of period $316,133 $318,599 $30,301 ======== ======== ======= Supplemental Disclosures of Cash Flow Information Cash paid/received during the year for: Interest paid $47,066 $37,111 $36,020 Interest received $24,348 $21,664 $20,079 Income taxes paid $73,276 $32,718 $12,896 Income taxes refunded $11,283 $7,693 $11,316 Table I PERRIGO COMPANY SEGMENT INFORMATION (in thousands) (unaudited) Fourth Quarter Fiscal Year -------------- ----------- 2009 2008 2009 2008 ---
'/>"/>

SOURCE Perrigo Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
Related medicine news :

1. Perrigo Company Announces Quarterly Dividend
2. Perrigo Company Will Release Fiscal Year 2009 Results on August 18, 2009
3. Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ
4. Perrigo Receives FDA Approval to Market Cherry and Cinnamon Flavored Nicotine Lozenges
5. Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal(R) Solution and Announcement of Lawsuit by Sepracor/UCB
6. Perrigo Reports Record Third Quarter
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
9. Perrigo Begins Shipments of Ibuprofen PM
10. Perrigo Reports Record Second Quarter Sales
11. Perrigo Company Announces Quarterly Dividend